Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.59 |
| ▸ | CYP4Z1 | Q86W10 | 2/20 | 0.58 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.55 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.53 |
| ▸ | CYP4F11 | Q9HBI6 | 1/20 | 0.52 |
| ▸ | CYP4F12 | Q9HCS2 | 1/20 | 0.52 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3675681 | 0.98 | ALOX5 (0.57) | ALOX5CYP4Z1GLAKMT2ACYP4F2 | |
| SCHEMBL1239542 | 0.95 | ALOX5 (0.65) | ALOX5CYP4Z1GLAKMT2ACYP4F2 | |
| SCHEMBL490909 | 0.89 | CYP4F2 (0.70) | ALOX5CYP4Z1GLAKMT2ACYP4F2 | |
| SCHEMBL9671800 | 0.89 | CYP4Z1 (0.65) | ALOX5CYP4Z1CYP4F2CYP4A11CYP4F11 | |
| SCHEMBL12548347 | 0.88 | CYP4Z1 (0.58) | ALOX5CYP4Z1CYP4F2CYP4A11L3MBTL1 | |
| SCHEMBL14570534 | 0.85 | CYP4Z1 (0.62) | ALOX5CYP4Z1CYP4F2CYP4A11LMNA | |
| SCHEMBL1237172 | 0.85 | F2RL1 (0.62) | ALOX5F2RL1CALM1 | |
| SCHEMBL8000090 | 0.85 | LTA4H (0.57) | CYP4Z1KMT2ACYP4F2CYP4A11LMNA | |
| SCHEMBL1052227 | 0.84 | PTGS2 (0.50) | ALOX5CYP4Z1CYP4F2CYP4A11 | |
| SCHEMBL432816 | 0.84 | CYP4F2 (0.64) | ALOX5CYP4Z1GLAKMT2ACYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9422240-B2 | Partially saturated nitrogen-containing heterocyclic compound | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2016-08-23 | — | — | US | disclosed |
| US-20150175541-A1 | PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2015-06-25 | — | — | US | disclosed |
| WO-2009113320-A1 | MMP INHIBITOR | 株式会社ヤクルト本社 (JP) | 2009-09-17 | — | — | WO | disclosed |
| US-20090062358-A1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONISTS | CANO IVAN COLLADO | 2009-03-05 | — | — | US | disclosed |
| US-20090062358-A1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONISTS | CANO IVAN COLLADO | 2009-03-05 | — | — | US | disclosed |
| EP-1335908-B1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONISTS | LILLY CO ELI (US) | 2008-02-13 | — | — | EP | disclosed |
| US-7304062-B2 | Peroxisome proliferator activated receptor alpha agonists | ELI LILLY AND COMPANY (US) | 2007-12-04 | — | — | US | disclosed |
| US-7304062-B2 | Peroxisome proliferator activated receptor alpha agonists | ELI LILLY AND COMPANY (US) | 2007-12-04 | — | — | US | disclosed |
| US-4334089-A | HYPOGLYCEMIC AGENTS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GESELLSCHAFT (DE) | 1982-06-08 | — | — | US | disclosed |
| EP-0051077-A1 | Substituted oxocarboxylic acids, process for their preparation, their use and medicines containing them | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1982-05-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175541-A1 | PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | EGLN2, EGLN3, EGLN1 | ALOX5 1919/4885CYP4Z1 1673/4885GLA 3688/4885 |
| US-20090062358-A1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONISTS | PPARG, PPARA, PPARD | ALOX5 474/4885CYP4Z1 618/4885GLA 2097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.